中国生物制药 Sino Biopharmaceutical
中国生物制药有限公司于二零零零年二月二日在开曼群岛注册成立之有限公司。本公司二零零零年九月二十九日在香港联合交易所创业板上市并于二零零三年十二月八日成功转至香港联合交易所主板上市，股份代号为1177。

本集团拥有优秀的制药企业管理和研发人才，拥有全国性的药品销售网络，拥有一流的已通过中国国家药品监督局GMP认证的：大容量注射剂、大容量注射剂(非PVC)、小容量注射剂、片剂、胶囊、颗粒剂、散剂等生产设施。

本集团的宗旨是透过不断开发创新生物药品及中药现代制剂，为病人带来健康，为股东创造价值。

本集团产品主要医疗领域为肝病、心脑血管疾病、老年病等。本集团也正在发展癌症、镇痛和呼吸道治疗领域的药物，以满足市场和广大的医生及患者的需要。

本公司主要下属公司为：
江苏正大天晴制药有限公司
北京泰德制药有限公司
南京正大天晴制药有限公司
江苏正大丰海制药有限公司
青岛正大海尔制药有限公司
江苏正大清江制药有限公司
正大邵阳骨伤科医院
上海通用药业股份有限公司
北京正大绿洲医药科技有限公司
 

凭借本集团多年来专注发展中国医药市场，尤以开发独家及专利药为主，掌握市场信息之余亦具备完善的销售网络，已成为国内重点医药企业之一。根据北京集琦医药网络有限公司最新公布的二零零五年中国医药统计报表数据显示，本集团附属公司江苏正大天晴药业股份公司（「江苏正大天晴」）、共同控制公司北京泰德制药有限公司（「北京泰德」）、长期投资公司正大青春宝药业有限公司（「正大青春宝」），按利润总额排名进一步向前推进，已挤身前五十强，可见本集团超卓的盈利能力。

美国《福布斯》(Forbes)将本公司评为2005年亚太地区10亿美元以下最佳公司之一。

Sino Biopharmaceutical Limited incorporated in the Cayman Islands with limited liability on 2 February, 2000. On 29 September 2000, the Company was listed on GEM of the Stock Exchange in Hong Kong and successfully commenced dealings in the Shares on the Main Board in Hong Kong on Dec 8, 2003 . Its ordinary shares are traded under the stock code 1177.

The Group has excellent talents specialized in management and R&D and a countrywide product sales network. The first-class production facilities for the volume injections, small volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines and granulated medicines, etc. have obtained the GMP certification from State Food and Drug Administration.

The Group's aims to bring healthier lives to people and greater value to its shareholders by developing innovative biopharmaceuticals and modernized Chinese medicines.

The Group produces medicines in two core therapeutic categories: cardio cerebral diseases and hepatitis. And it is extending development efforts to oncology, analgesic and respiratory medicines, in order to meet the increasing demands of medical practitioners and patients.

Main subsidiaries or jointly controlled entities:

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.

Beijing Tide Pharmaceutical Co., Ltd.

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Qingdao Chia Tai Haier Pharmaceutical Co., Ltd.

Jiangsu Chia Tai Qing Jiang Pharmaceutical Co., Ltd.

Chia Tai Shaoyang Orthopedic Hospital

Shanghai General Pharmaceutical Co., Ltd.

Beijing Chia Tai Green Continent Pharmaceutical Co., Ltd.

Being one of the most prominent pharmaceutical enterprises in the PRC, the Group's core competencies include its strategic focus on the Chinese pharmaceutical market, its abilities to develop exclusive proprietary drugs, to effectively collect market information, and to operate a comprehensive sales network. According to the Chinese Medicine Annual Report 2005 issued by Beijing JiQi, the Group's subsidiaries and its jointly-controlled entity, namely Jiangsu Chia Tai Tianqing Pharmaceutical Co. Ltd. (JCTT), Beijing Tide Pharmaceutical Co. Ltd. (Beijing Tide), and Chia Tai Qingchunbao Pharmaceutical Co. Ltd (the Group's long-term investment), all ranked amongst the top fifty enterprises in the industry in terms of profitability.

Forbes selected the Group as one of the Best 2005 Asian Companies Under A Billion.